ArticleEuropean heart journal. Cardiovascular Imaging2023
Cardiac magnetic resonance in giant cell myocarditis: a matched comparison with cardiac sarcoidosis.
Article in European heart journal. Cardiovascular Imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Giant cell myocarditis: from immune pathogenesis to contemporary management.Heart failure reviews · 2026Review
- Multiparametric CMR in Myocarditis: A Comprehensive Review of Diagnostic Advances, Prognostic Value, and the Challenge of Genetic Mimics.Biomedicines · 2026Review
- Cardiac Sarcoidosis: Pathophysiology and Diagnostic-Therapeutic Processes.Reviews in cardiovascular medicine · 2026Review
- Cardiovascular magnetic resonance imaging and endomyocardial biopsy in giant cell myocarditis: a case report on diagnostic challenges and future perspectives.European heart journal. Case reports · 2025Article
- Late Gadolinium Enhancement Magnetic Resonance Imaging (MRI) for Predicting Left Ventricular Reverse Remodeling in Non-Ischemic Cardiomyopathy: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- The Clinical and Histological Intersection of Cardiac Sarcoidosis and Giant Cell Myocarditis.Cureus · 2024Article
- Giant cell myocarditis with prolonged cardiac standstill after drug-induced hypersensitivity syndrome: a case report.ESC heart failure · 2024Article
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Unraveling the Uncommon: A Case Report of Giant Cell Myocarditis and Examination of Existing Literature.The American journal of case reports · 2024Review
- Cardiac magnetic resonance in histologically proven eosinophilic myocarditis.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2023Article
- Biomarkers in Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Updated Review of the Literature.Journal of clinical medicine · 2023Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsGiant cell myocarditis (GCM) is an inflammatory cardiomyopathy akin to cardiac sarcoidosis (CS). We decided to study the findings of GCM on cardiac magnetic resonance (CMR) imaging and to compare GCM with CS. METHODS AND
resultsCMR studies of 18 GCM patients were analyzed and compared with 18 CS controls matched for age, sex, left ventricular (LV) ejection fraction and presenting cardiac manifestations. The analysts were blinded to clinical data. On admission, the duration of symptoms (median) was 0.2 months in GCM vs. 2.4 months in CS (P = 0.002), cardiac troponin T was elevated (>50 ng/L) in 16/17 patients with GCM and in 2/16 with CS (P < 0.001), their respective median plasma B-type natriuretic propeptides measuring 4488 ng/L and 1223 ng/L (P = 0.011). On CMR imaging, LV diastolic volume was smaller in GCM (177 ± 32 mL vs. 211 ± 58 mL, P = 0.014) without other volumetric or wall thickness measurements differing between the groups. Every GCM patient had multifocal late gadolinium enhancement (LGE) in a distribution indistinguishable from CS both longitudinally, circumferentially, and radially across the LV segments. LGE mass averaged 17.4 ± 6.3% of LV mass in GCM vs 25.0 ± 13.4% in CS (P = 0.037). Involvement of insertion points extending across the septum into the right ventricular wall, the "hook sign" of CS, was present in 53% of GCM and 50% of CS.
conclusionIn GCM, CMR findings are qualitatively indistinguishable from CS despite myocardial inflammation being clinically more acute and injurious. When matched for LV dysfunction and presenting features, LV size and LGE mass are smaller in GCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.